Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Busulfan

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    66 result(s) found for: Busulfan. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2020-003392-17 Sponsor Protocol Number: BUSEQ-IPC2020-006 Start Date*: 2021-02-17
    Sponsor Name:Institut Paoli-Calmettes
    Full Title: SEQUENTIAL AND PERSONALIZED BUSULFAN ADMINISTRATION BY PHARMACOKINETICS IN ALLOGENIC GRAFT CONDITIONING FOR PATIENTS WITH MALIGNANT HEMOPATHIA NOT ELIGIBLE FOR STANDARD MYELOABLATIVE PACKAGIN
    Medical condition: Acute Leukemia Mielodysplasic Syndrome Myeloproliferative Neoplasm
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000758-12 Sponsor Protocol Number: BX-PK-IPC2013-016 Start Date*: 2014-05-30
    Sponsor Name:INSTITUT PAOLI CALMETTES
    Full Title: Study of pharmacokinetics of intravenous busulfan (Busilvex ®) in the conditioning allogeneic transplantation in patients with high-risk hematological disease.
    Medical condition: hematological malignancies : Acute Myeloblastic Leukemia, Chronic Lymphoïd Leukemia, Multiple myéloma, Acute lymphoblastic leukemia.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    17.0 100000004864 10000878 Acute myeloblastic leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003658-13 Sponsor Protocol Number: EWING2008 Start Date*: 2009-03-19
    Sponsor Name:Universitaetsklinikum Muenster
    Full Title: EWING 2008
    Medical condition: Ewing sarcoma Malignant peripheral neuroectodermal tumour Askin tumour Atypical Ewing sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057846 Primitive neuroectodermal tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057656 Askin's tumour LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015759 Extra-osseous Ewing's sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) BE (Completed) NL (Completed) SE (Completed) HU (Completed) FI (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005803-16 Sponsor Protocol Number: GITMOAMLR.2 Start Date*: 2007-12-24
    Sponsor Name:GITMO (GRUPPO ITALIANO DI MIDOLLLO OSSEO)
    Full Title: RANDOMIZED STUDY COMPARING INTRAVENOUS BUSULFAN (I.V. BU; BUSILVEX) PLUS FLUDARABINE (BUFLU) VERSUS INTRAVENOUS BUSULFAN PLUS CYCLOPHOSPHAMIDE (BUCY2) AS CONDITIONING REGIMENS PRIOR TO ALLOGENEIC H...
    Medical condition: Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000981-46 Sponsor Protocol Number: IC2015-13 Start Date*: Information not available in EudraCT
    Sponsor Name:INSTITUT CURIE
    Full Title: First-line treatment of Ewing tumours with primary extrapulmonary dissemination in patients from 2 to 50 years -
    Medical condition: First-line treatment of Ewing tumours with primary extrapulmonary dissemination in patients from 2 to 50 years
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055101 Bone cancer metastatic PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005683-10 Sponsor Protocol Number: GEM2012MENOS65 Start Date*: 2013-07-23
    Sponsor Name:FUNDACIÓN PETHEMA
    Full Title: Estudio fase III nacional, multicéntrico, abierto, aleatorizado, de tratamiento de inducción con bortezomib/lenalidomida/dexametasona (VRD-GEM), seguido de altas dosis de quimioterapia con melfalán...
    Medical condition: Multiple myeloma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022052-23 Sponsor Protocol Number: ProtocolCodeGITMO-MF2010 Start Date*: 2011-04-20
    Sponsor Name:GITMO GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO,CELLULE STAMINALI EMOPOIETICHE E TERAPIA CELLULARE - ONLUS
    Full Title: Prospective, phase II randomized study to compare busulfan-fludarabine reduced-intensity conditioning (RIC) with thiotepa-fludarabine RIC regimen prior to allogeneic transplantation of hematopoieti...
    Medical condition: Primary or secondary myelofibrosis after essential thrombocytemia or polycyhemia vera
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005378-73 Sponsor Protocol Number: TBF2012 Start Date*: 2013-01-29
    Sponsor Name:FONDAZIONE NEOPLASIE SANGUE ONLUS
    Full Title: Allogeneic Transplantation after a Conditioning with Thiotepa, Busulfan and Fludarabin for the treatment of refractory/early relapsed aggressive B-cell non Hodgkin lymphomas: a Phase II Multi-Cente...
    Medical condition: Refractory/early relapsed aggressive B-cell non Hodgkin lymphomas
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003899 B-cell lymphoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001068-31 Sponsor Protocol Number: 2019/2894 Start Date*: 2019-09-24
    Sponsor Name:Gustave Roussy
    Full Title: High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) Randomized, international and multicentric phase 3 study that evaluates and compares 2 treatment strategies in 3 therapeutic p...
    Medical condition: Very High Risk Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029261 Neuroblastoma NOS LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) SI (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) SE (Ongoing) SK (Trial now transitioned) ES (Ongoing) DE (Ongoing) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-005508-33 Sponsor Protocol Number: MC-FludT.16/NM Start Date*: 2014-09-29
    Sponsor Name:medac Gesellschaft für klinische Spezialpräparate mbH
    Full Title: Clinical phase II trial to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation (HSCT) in paediatric patients ...
    Medical condition: Male and female children with non-malignant diseases requiring myeloablative conditioning treatment with following allogeneic haematopoietic stem cell transplantation (allo-HSCT) – i.e. primary imm...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10021606 Inborn errors of metabolism NEC HLT
    20.0 100000004870 10036700 Primary immunodeficiency syndromes HLT
    20.0 100000004850 10018903 Haemoglobinopathies congenital HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) CZ (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002356-18 Sponsor Protocol Number: MC-FludT.14/L Start Date*: 2010-01-12
    Sponsor Name:medac Gesellschaft für klinische Spezialpräparate mbH
    Full Title: Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in pa...
    Medical condition: Patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) considered ineligible to standard conditioning therapies prior to allogeneic stem cell transplantation.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000881 Acute myeloid leukaemia (in remission) PT
    20.0 100000013034 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) PL (Completed) FI (Prematurely Ended) FR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-003032-22 Sponsor Protocol Number: ALL-SCT-ped-FORUM Start Date*: 2013-02-04
    Sponsor Name:St. Anna Kinderkrebsforschung GmbH
    Full Title: Allogenic stem cell transplantation in children and adolescents with acute lymphoblastic leukaemia - FORUM
    Medical condition: acute lymphoblastic leukaemia
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) DE (Trial now transitioned) NO (Trial now transitioned) FI (Completed) DK (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) SE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002172-39 Sponsor Protocol Number: VX21-CTX001-141 Start Date*: 2021-10-05
    Sponsor Name:VERTEX PHARMACEUTICALS INCORPORATED
    Full Title: A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Transfusion-Dependent ß-Thalassemia
    Medical condition: Transfusion-Dependent ß Thalassemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10054660 Thalassemia beta LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000673-68 Sponsor Protocol Number: 16IC17 Start Date*: 2018-10-09
    Sponsor Name:Great Ormond Street Hospital for Children NHS Trust
    Full Title: Phase I/II study of lentiviral gene transfer for SCID-X1 with low dose targeted busulfan
    Medical condition: Severe combined immunodeficiency disorder (SCID) is a heterogeneous group of inherited disorders characterized by a profound reduction or absence of T lymphocyte function, resulting in lack of both...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10069566 Severe combined immunodeficiency syndrome LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-016601-42 Sponsor Protocol Number: F60002 IN 202 G0 Start Date*: 2010-02-03
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: A phase II multicentric study in adults with acute myelogenous leukaemia (AML) in first complete remission (CR1) using IV BuCy2 in a once daily Bu regimen targeting a narrow therapeutic window prio...
    Medical condition: Acute myeloid leukaemia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10000881 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003282-36 Sponsor Protocol Number: 123123 Start Date*: Information not available in EudraCT
    Sponsor Name:Västra Götalands Regionen
    Full Title: A Randomized, Multi-Center Phase III Trial comparing two conditioning regimens (CloFluBu and BuCyMel) in children with Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation.
    Medical condition: Acute myeloid leukemia (AML) in children
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001075-37 Sponsor Protocol Number: TUD-FHCRCD-010 Start Date*: 2007-05-18
    Sponsor Name:University of Technology Dresden
    Full Title: A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplantation in Patients with Myelodysplastic Syndrome or Acute Myelogenous Leukemia.
    Medical condition: MDS and AML are predominantly diseases of older patients. For patients with advanced or chemotherapy refractory disease HCT is currently the only strategy that offers curative therapy. Unfortunat...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014980-38 Sponsor Protocol Number: TJB0909P1 Start Date*: 2010-07-06
    Sponsor Name:CHU de Liège
    Full Title: Co-transplantation of mesenchymal stem cells and HLA-mismatched allogeneic hematopoietic cells after reduced-intensity conditioning: a phase II randomized double-blind study.
    Medical condition: Hematological malignancies confirmed histologically and not rapidly progressing: - AML in Complete Remission; - ALL in Complete Remission; - CML unresponsive/intolerant to Imatinib but not in b...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10027703 Mismatched donor bone marrow transplantation therapy PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001181-10 Sponsor Protocol Number: P003077 Start Date*: 2023-04-13
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a rand...
    Medical condition: Primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) is a rare lymphoma affecting only the central nervous system compartment. PCNSL patients are typically 60 years or older ...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006390-37 Sponsor Protocol Number: VX21-CTX001-161 Start Date*: Information not available in EudraCT
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects with Transfusion-Depend...
    Medical condition: Transfusion-dependent β-thalassemia (TDT) and severe sickle cell disease (SCD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    20.1 10010331 - Congenital, familial and genetic disorders 10054660 Thalassemia beta LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 22 23:51:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA